started · updated
EU approves updated Pfizer‑BioNTech Comirnaty vaccine targeting XFG variant
The European Commission has granted marketing authorization for the 2026‑2027 formulation of the Pfizer‑BioNTech mRNA COVID‑19 vaccine, Comirnaty, revised to target the XFG (Stratus) SARS‑CoV‑2 variant. The approval follows the European Medicines Agency (EMA) task force recommendation that XFG, a sub‑variant of the Omicron JN.1 family, should be the vaccine target for the upcoming respiratory‑illness season.
The updated monovalent vaccine is authorised for use in individuals aged six months and older across all 27 EU Member States and the European Economic Area members Iceland, Liechtenstein and Norway. Pfizer and BioNTech have already begun production, with shipments expected to start soon to ensure availability for the autumn‑winter vaccination campaign.
XFG became the predominant circulating strain after a rapid rise from June 2025, representing about 74 % of sequenced cases in October 2025. The EMA’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion based on clinical, pre‑clinical and real‑world data presented by the manufacturers.
Entities
Comirnaty · European Commission · European Medicines Agency · Pfizer‑BioNTech · XFG variant